NasdaqGS - Delayed Quote • USD
Cabaletta Bio, Inc. (CABA)
At close: 4:00 PM EDT
After hours: 4:58 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 10 | 10 |
| Avg. Estimate | -0.55 | -0.54 | -2.13 | -2.19 |
| Low Estimate | -0.73 | -0.62 | -2.38 | -2.88 |
| High Estimate | -0.44 | -0.44 | -1.83 | -0.99 |
| Year Ago EPS | -0.37 | -0.37 | -1.65 | -2.13 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | 8.33M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 50M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.44 | -0.4 | -0.39 | -0.48 |
| EPS Actual | -0.37 | -0.37 | -0.46 | -0.51 |
| Difference | 0.07 | 0.03 | -0.07 | -0.03 |
| Surprise % | 15.90% | 7.50% | -17.90% | -6.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.55 | -0.54 | -2.13 | -2.19 |
| 7 Days Ago | -0.55 | -0.54 | -2.13 | -2.23 |
| 30 Days Ago | -0.47 | -0.47 | -1.9 | -2.09 |
| 60 Days Ago | -0.47 | -0.47 | -1.89 | -2.11 |
| 90 Days Ago | -0.43 | -0.43 | -1.72 | -1.89 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CABA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -48.60% | -- | -- | 7.90% |
| Next Qtr. | -45.90% | -- | -- | 10.20% |
| Current Year | -29.10% | -- | -- | 4.80% |
| Next Year | -2.80% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/24/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/16/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
| Maintains | Citigroup: Buy to Buy | 4/4/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/22/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/22/2024 |
Related Tickers
KYTX Kyverna Therapeutics, Inc.
13.23
+1.77%
PLRX Pliant Therapeutics, Inc.
12.88
+1.18%
NKTX Nkarta, Inc.
6.47
+0.47%
STOK Stoke Therapeutics, Inc.
14.07
-2.39%
SANA Sana Biotechnology, Inc.
7.80
-2.74%
AKRO Akero Therapeutics, Inc.
19.50
+6.44%
ALXO ALX Oncology Holdings Inc.
12.56
-4.63%
IMTX Immatics N.V.
11.67
-0.26%
CRNX Crinetics Pharmaceuticals, Inc.
46.86
-1.29%
IMCR Immunocore Holdings plc
46.30
+0.54%